Ayman Al-Hendy to Quality of Life
This is a "connection" page, showing publications Ayman Al-Hendy has written about Quality of Life.
Connection Strength
1.977
-
Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary. J Comp Eff Res. 2024 08; 13(8):e230194.
Score: 0.519
-
Quality of life improvements in women with uterine fibroids treated with relugolix combination therapy during the LIBERTY long-term extension study: A descriptive subgroup analysis in women with anemia at baseline. Int J Gynaecol Obstet. 2024 May; 165(2):431-441.
Score: 0.128
-
Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases-Focus on Epigenetic Mechanisms. Nutrients. 2024 Feb 17; 16(4).
Score: 0.127
-
Fibroids and unexplained infertility treatment with epigallocatechin gallate: a natural compound in green tea (FRIEND) - protocol for a randomised placebo-controlled US multicentre clinical trial of EGCG to improve fertility in women with uterine fibroids. BMJ Open. 2024 01 12; 14(1):e078989.
Score: 0.126
-
Evidence-Based Approach for Secondary Prevention of Uterine Fibroids (The ESCAPE Approach). Int J Mol Sci. 2023 Nov 04; 24(21).
Score: 0.124
-
Current and Emerging Treatment Options for Uterine Fibroids. Drugs. 2023 Dec; 83(18):1649-1675.
Score: 0.124
-
LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol. 2023 12; 229(6):662.e1-662.e25.
Score: 0.123
-
Uterine Fibroids: A Podcast on Patient and Physician Perspectives on Medical Management and a New Medical Therapy (Relugolix Combination Therapy). Adv Ther. 2023 10; 40(10):4127-4133.
Score: 0.122
-
Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials. Am J Obstet Gynecol. 2023 03; 228(3):320.e1-320.e11.
Score: 0.116
-
Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women. J Womens Health (Larchmt). 2018 11; 27(11):1359-1367.
Score: 0.087
-
Uterine Leiomyoma: New Perspectives on an Old Disease. Semin Reprod Med. 2017 11; 35(6):471-472.
Score: 0.082
-
Uterine Fibroids: Burden and Unmet Medical Need. Semin Reprod Med. 2017 11; 35(6):473-480.
Score: 0.082
-
Surgical myomectomy followed by oral Myfembree vs standard of care (SOUL trial): Study protocol for a randomized control trial. PLoS One. 2024; 19(7):e0306053.
Score: 0.032
-
Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study. Am J Obstet Gynecol. 2024 02; 230(2):237.e1-237.e11.
Score: 0.031
-
Standardising outcome reporting for clinical trials of interventions for heavy menstrual bleeding: Development of a core outcome set. BJOG. 2023 10; 130(11):1337-1345.
Score: 0.030
-
Adverse childhood experiences and health-related quality of life among women undergoing hysterectomy for uterine leiomyoma. Am J Obstet Gynecol. 2022 08; 227(2):351-353.e5.
Score: 0.028
-
A Call-to-Action for Clinicians to Implement Evidence-Based Best Practices When Caring for Women with Uterine Fibroids. Reprod Sci. 2022 04; 29(4):1188-1196.
Score: 0.028
-
Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. Obstet Gynecol. 2020 06; 135(6):1313-1326.
Score: 0.024
-
Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. N Engl J Med. 2020 01 23; 382(4):328-340.
Score: 0.024
-
Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2018 11; 132(5):1252-1264.
Score: 0.022